Latest & greatest articles for stroke

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on stroke or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on stroke and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for stroke

1901. Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation

Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Green C J, Hadorn D, Kazanjian A Authors' objectives To assess the evidence concerning the outcomes associated with efforts to prevent the occurrence of stroke in patients with chronic non-valvular atrial fibrillation using warfarin sodium. Searching (...) MEDLINE was searched from 1987 to 1994 using the keywords: 'atrial fibrillation', 'anticoagulants', 'aspirin'). Reference lists of retrieved articles were sought. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) on the efficacy of warfarin sodium in the primary prevention of stroke in chronic non-valvular atrial fibrillation were included. Specific interventions included in the review The specific intervention was anticoagulation, i.e. warfarin

DARE.1995

1902. Is ambulatory electrocardiography useful in the evaluation of patients with recent stroke

Is ambulatory electrocardiography useful in the evaluation of patients with recent stroke Is ambulatory electrocardiography useful in the evaluation of patients with recent stroke Is ambulatory electrocardiography useful in the evaluation of patients with recent stroke Kessler D K, Kessler K M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ambulatory Electrocardiography (AECG) in recent stroke. Type of intervention Diagnosis and Treatment. Economic study type Cost-effectiveness analysis. Study population Patients undergoing AECG, aged 64 + Setting Ambulatory setting. The economic study was performed in Miami, USA. Dates to which data relate The date to which data relate and the prices used are both unclear. Source

NHS Economic Evaluation Database.1995

1903. Acute and subacute rehabilitation for stroke: a comparison

Acute and subacute rehabilitation for stroke: a comparison Acute and subacute rehabilitation for stroke: a comparison Acute and subacute rehabilitation for stroke: a comparison Keith R A, Wilson D B, Gutierrez P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The comparative merits of acute and subacute rehabilitation for stroke. Type of intervention Rehabilitation. Economic study type Cost-effectiveness analysis. Study population Patients with left or right hemiplegia, discharged from the acute and subacute facilities and who had admission and discharge Functional Impairment Measures (FIM) ratings. Setting Hospital and skilled nursing unit. The economic study was carried out in the USA. Dates to which data relate

NHS Economic Evaluation Database.1995

1904. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost - a community-based study

The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost - a community-based study The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost - a community-based study The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost - a community-based study Jorgensen H S, Nakayama H, Raaschou H O, Larsen K, Hubbe P (...) , Olsen T S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment and aftercare for stroke patients in a dedicated stroke care unit. Type of intervention Treatment; rehabilitation. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.1995

1905. Stroke Prevention: Recommendations

Stroke Prevention: Recommendations Stroke Prevention: Recommendations Stroke Prevention: Recommendations Research Findings for Clinicians The Secondary and Tertiary Prevention of Stroke Patient Outcomes Research Team (PORT) has established important findings about the most cost-effective treatments for people at high risk for stroke. The PORT is a 5-year research study supported by the Agency for Health Care Policy and Research (AHCPR). These findings have led to the following recommendations (...) for the treatment of patients with atrial fibrillation (select [15 KB]) and transient ischemic attack (TIA)/minor stroke (select [26 KB]). Patients with Atrial Fibrillation Prescribe Warfarin Unless Risk of Stroke Is Low or Use Is Contraindicated Anticoagulant treatment is particularly effective for patients with atrial fibrillation and any one of the following additional risk factors: over age 60, prior stroke, diabetes, hypertension, and heart disease. Aspirin may be used if warfarin is contraindicated

Publication 3241995

1906. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. 7491044 1996 01 02 1996 01 02 2015 06 16 0140-6736 346 8989 1995 Dec 09 Lancet (London, England) Lancet Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. 1509-14 In ischaemic stroke, thrombolytic drugs (...) speed the recanalisation of intracerebral arteries. The effects of aspirin are not known. A trial was conducted to determine whether, separately or together, streptokinase and aspirin have clinical benefits in acute ischaemic stroke similar to those in acute myocardial infarction. 622 patients with acute ischaemic stroke within 6 hours of symptom onset were randomised with a 2 x 2 factorial design to (i) a 1-hour intravenous infusion of 1.5 MU streptokinase, (ii) 300 mg/day buffered aspirin for 10

Lancet1995

1907. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 7477192 1995 12 19 1995 12 19 2010 03 24 0028-4793 333 24 1995 Dec 14 The New England journal of medicine N. Engl. J. Med. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1581-7 Thrombolytic therapy for acute ischemic stroke has been approached cautiously because (...) there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within three hours of the onset of stroke. The trial had two parts. Part 1 (in which 291 patients were enrolled) tested whether t-PA had clinical activity, as indicated by an improvement of 4 points over base-line

NEJM1995

1908. Low-molecular-weight heparin for the treatment of acute ischemic stroke.

Low-molecular-weight heparin for the treatment of acute ischemic stroke. 7477193 1995 12 19 1995 12 19 2010 03 24 0028-4793 333 24 1995 Dec 14 The New England journal of medicine N. Engl. J. Med. Low-molecular-weight heparin for the treatment of acute ischemic stroke. 1588-93 Despite doubts about their efficacy and concern about their safety, antithrombotic agents are often used to treat acute ischemic stroke. Recent experience in patients with other thromboembolic disorders suggests (...) that low-molecular-weight heparin, which requires only subcutaneous administration once or twice daily, may be more effective and safer than standard (unfractionated) heparin. We conducted a randomized, double-blind, placebo-controlled trial comparing two dosages of low-molecular-weight heparin with placebo in the treatment of ischemic stroke. Patients were randomly assigned within 48 hours of the onset of symptoms to receive high-dose nadroparin (4100 anti-factor Xa IU twice daily), low-dose nadroparin (4100 IU once daily

NEJM1995

1909. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) 7563451 1995 10 26 1995 10 26 2016 11 23 0098-7484 274 13 1995 Oct 04 JAMA JAMA Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) 1017-25 To evaluate the efficacy and safety of intravenous thrombolysis using recombinant tissue plasminogen (...) activator (rt-PA) in patients with acute ischemic stroke. Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. A total of 75 hospitals in 14 European countries. A total of 620 patients with acute ischemic hemispheric stroke and moderate to severe neurologic deficit and without major early infarct signs on initial computed tomography (CT). Patients were randomized to treatment with 1.1 mg per kilogram of body weight of rt-PA (alteplase) or placebo within 6 hours from

JAMA1995

1910. Risk of stroke in the distribution of an asymptomatic carotid artery. The European Carotid Surgery Trialists Collaborative Group.

Risk of stroke in the distribution of an asymptomatic carotid artery. The European Carotid Surgery Trialists Collaborative Group. 7823712 1995 02 16 1995 02 16 2016 11 23 0140-6736 345 8944 1995 Jan 28 Lancet (London, England) Lancet Risk of stroke in the distribution of an asymptomatic carotid artery. The European Carotid Surgery Trialists Collaborative Group. 209-12 Screening and carotid endarterectomy have been advocated for asymptomatic carotid stenosis. However, the risk of stroke without (...) treatment has not been adequately defined. We investigated the risk of stroke in the distribution of the asymptomatic carotid artery in 2295 patients randomised in the European Carotid Surgery Trial. During a mean follow-up of 4.5 years, there were 69 carotid territory strokes, nine of which were fatal, giving three year Kaplan-Meier risks of stroke and fatal stroke of 2.1% (95% Cl, 1.5-2.8) and 0.3% (95% Cl, 0.06-0.56) respectively. The stroke risk in the 127 patients with severe (70-99%) carotid

Lancet1995

1911. Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia

Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia Effect of aspirin on risk of stroke or death in women who have suffered cerebral ischemia Jonas S Authors' objectives To investigate the effect of aspirin on occurrence of stroke or death in women who have previously suffered cerebral ischaemia. Searching Studies were identified by searching MEDLINE, and English (...) -language medical, neurological and stroke journals; by examining previous meta-analyses; and by discussion with colleagues at international and national stroke meetings. Study selection Study designs of evaluations included in the review Randomised double-blind trials were included. Specific interventions included in the review Aspirin; placebo. Participants included in the review Patients who had suffered transient ischaemia or stroke in the carotid or vertebrobasilar artery territories, were included

DARE.1994

1912. Medical treatment for stroke prevention

Medical treatment for stroke prevention Medical treatment for stroke prevention Medical treatment for stroke prevention Matchar D B, McCrory D C, Barnett H J, Feussner J R Authors' objectives To review the effectiveness of medical treatments for stroke prevention in patients at elevated risk of stroke. Searching English language studies published between 1977 and 1993 were identified through MEDLINE and Current Contents on disk. This was supplemented by a search of references of pertinent (...) reviews, textbooks and published guidelines. The medical subject headings used were: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs). Specific interventions included in the review Anticoagulant and platelet antiaggregant treatments. Participants included in the review Men and women with elevated risk of stroke (asymptomatic cartoid

DARE.1994

1913. Efficacy of electromyographic biofeedback compared with conventional physical therapy for upper-extremity function in patients following stroke: a research overview and meta-analysis

Efficacy of electromyographic biofeedback compared with conventional physical therapy for upper-extremity function in patients following stroke: a research overview and meta-analysis Efficacy of electromyographic biofeedback compared with conventional physical therapy for upper-extremity function in patients following stroke: a research overview and meta-analysis Efficacy of electromyographic biofeedback compared with conventional physical therapy for upper-extremity function in patients (...) following stroke: a research overview and meta-analysis Moreland J, Thomson M A Authors' objectives To examine the efficacy of electromyographic (EMG) biofeedback compared to conventional physical therapy, for improving upper-extremity function in patients following a stroke. Searching MEDLINE was searched with the keywords 'electromyography', biofeedback' and 'cerebrovascular disorders'; CINAHL with the keywords 'biofeedback' and 'cerebrovascular accident'; and Dissertation Abstracts International

DARE.1994

1914. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients

Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients Oster G, Huse D M, Lacey M J, Epstein A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Antiplatelet agents to reduce the risk of stroke in high-risk patients. In particular the use of ticlopidinevs aspirin was considered. Type of intervention Secondary prevention Economic study type Cost-effectiveness and cost-utility analyses. Study population A hypothetical cohort of 100 patients aged 65 when the therapy was initiated, who could be defined as high risk, i.e. with a recent

NHS Economic Evaluation Database.1994

1915. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. 7907677 1994 04 20 1994 04 20 2015 06 16 0140-6736 343 8899 1994 Mar 19 Lancet (London, England) Lancet Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. 687-91 Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation (...) , but the value of this agent relative to aspirin in unclear. In the first Stroke Prevention in Atrial Fibrillation (SPAF-I) study, direct comparison of warfarin with aspirin was limited by the small number of thromboembolic events. SPAF-II aims to address this issue and also to assess the differential effects of the two treatments according to age. We compared warfarin (prothrombin time ratio 1.3-1.8, international normalised ratio 2.0-4.5) with aspirin 325 mg daily for prevention of ischaemic stroke and

Lancet1994

1916. Citalopram for post-stroke pathological crying.

Citalopram for post-stroke pathological crying. 8104273 1993 10 21 1993 10 21 2015 06 16 0140-6736 342 8875 1993 Oct 02 Lancet (London, England) Lancet Citalopram for post-stroke pathological crying. 837-9 Post-stroke pathological crying is a distressing condition in which episodes occur in response to minor stimuli without associated mood changes. There is preliminary evidence of disturbed serotoninergic neurotransmission in such cases. We investigated the effect (...) of the selective serotonin reuptake inhibitor citalopram on uncontrolled crying in stroke patients in a double-blind placebo-controlled crossover study. 16 consecutive patients (median age 58.5 years, range 40-83) entered the 9-week study a median of 168 days (range 6-913) post stroke and were treated with citalopram 10-20 mg daily for 3 weeks. Crying history was determined from semistructured interviews and from diaries kept by the patients. Psychiatric assessment was made with the Hamilton depression scale (HDS), and unwanted effects

Lancet1993

1917. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. 7901582 1993 12 09 1993 12 09 2015 06 16 0140-6736 342 8882 1993 Nov 20 Lancet (London, England) Lancet Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. 1255-62 Several studies have established the value of anticoagulation (...) for primary prevention of thromboembolic events in patients with non-rheumatic atrial fibrillation (NRAF). However, in patients with a recent transient ischaemic attack (TIA) or minor ischaemic stroke the preventive benefit of anticoagulation or aspirin remains unclear. Physicians in 108 centres from 13 countries collaborated to study this question. 1007 NRAF patients with a recent TIA or minor ischaemic stroke were randomised to open anticoagulation or double-blind treatment with either 300 mg aspirin

Lancet1993

1918. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis.

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Anticardiolipin antibodies and th... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1992 ) Volume: 117 , Issue: 12 , Pages: 997-1002 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and (...) was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus. MEASUREMENTS: Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme

Annals of Internal Medicine1992

1919. Stroke

Stroke Stroke Stroke Wester PO, Asplund K, Eriksson S, Holm J, Marke L A, Norlund A, Norrving B, Normell L, Rehncrona S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wester PO, Asplund K, Eriksson S, Holm J, Marke L A, Norlund A, Norrving B, Normell L, Rehncrona S. Stroke. Stockholm: Swedish Council on Technology Assessment in Health (...) Care (SBU) 1992: 129 Authors' objectives To summarise and critically analyse the current facts concerning the prevention, diagnosis, treatment and rehabilitation of stroke. Authors' conclusions The most important aim should be to prevent stroke. Controlled studies have demonstrated that some interventions, such as adequate treatment of high blood pressure, anticoagulation treatment, surgical treatment, acetylsalicylic acid treatment and intervention against smoking for appropriate patients under

Health Technology Assessment (HTA) Database.1992

1920. Stroke rehabilitation

Stroke rehabilitation Stroke rehabilitation Stroke rehabilitation NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Stroke rehabilitation. University of York. Effective Health Care 1(2). 1992 Authors' objectives To assess whether formal rehabilitation reduces (...) disability and handicap and improves quality of life for people who have suffered a stroke. Authors' conclusions Much more research is required to establish which aspects of stroke rehabilitation are most effective. Further good quality research is required to inform a variety of decisions on the use of specific rehabilitation services in different settings. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cerebrovascular Disorders; Rehabilitation Language Published English Country

Health Technology Assessment (HTA) Database.1992